News

2011 | 2010 | 2009 | 2008 | 2007 | 2006

 

London, 3 November2011

 

ImmuPharma’s Lupuzor™ granted approval to start phase III and Fast Track designation by the FDA

ImmuPharma plc (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist discovery and development pharmaceutical company is pleased to provide an update on the development status of its Lupus drug candidate Lupuzor™.

 

Click here for more details


London, 21 October 2011

 

ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce that following discussions with Cephalon Inc (Cephalon), its licensee for Lupuzor™, it has regained rights to Lupuzor™, due to the acquisition of Cephalon by Teva Pharmaceutical Industries Ltd (Teva).

 

Click here for more details


London, 30 September 2011

 

INTERIM RESULTS ANNOUNCEMENT
For the six months ended 30 June 2011

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2011.

 

Click here for more details


London, 23 September 2011

 

Notification of Interim Results Date: 30 September 2011

ImmuPharma PLC (AIM:IMM), the specialist discovery and development pharmaceutical company, is scheduled to announce its Interim Results for the six months ended 30 June 2011 on 30 September 2011.

 

Click here for more details


London, 12 July  2011

 

Notification of Major Interest in Shares 

 

Click here for more details


London, 19 May  2011

 

Result of Annual General Meeting

ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.

 

Click here for more details


London, 05 May  2011

 

Cancer Compound IPP-204106 paper published
in prestigious medical journal

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce the publication of a scientific paper on its cancer compound IPP-204106 in Cancer Research, a prestigious medical journal of the American Association for Cancer Research.

 

Click here for more details


London, 26 April 2011

 

Annual Report and Accounts
Notice of Annual General Meeting: 19 May 2011

In accordance with Rule 20 of the AIM Rules, ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2010, has been posted to shareholders.

 

Click here for more details


London, 5 April 2011

 

PRELIMINARY RESULTS ANNOUNCEMENT
for the year ended 31 December 2010

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is pleased to announce its preliminary audited results for the year ended 31 December 2010.

 

Click here for more details


London,  21 February 2011

 

Update on progress of Phase I/IIa Clinical Trial with IPP-204106: Cancer patients stabilised with ImmuPharma's Cancer Compound

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company"or the  "Group"), the specialist discovery and development pharmaceutical company is pleased to announce encouraging results from its ongoing phase I/IIa clinical trial in cancer patients.

Key Highlights:

Around half of the cancer patients that have undergone treatment with ImmuPharma's drug candidate IPP-204106 are in stable condition (their disease has stopped progressing) without any other drug treatment.  All the patients that enrolled in the study were suffering from advanced cancer with metastases and had all failed their previous treatments with other existing cancer drugs.

Click here for more details


London, 19 October 2010

 

Update on Phase IIa Clinical Trial with
Cancer Compound IPP-204106

 

Click here for more details


London, 11 October 2010

 

ADDITIONAL LISTING AND TOTAL VOTING RIGHTS
PICTET INCREASE HOLDING TO OVER 3%

 

Click here for more details


London, 30 September 2010

 

INTERIM RESULTS ANNOUNCEMENT
for the six months ended 30 June 2010

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2010.

INTERIM HIGHLIGHTS

  • First patients dosed with IPP-204106, ImmuPharma's anti-cancer compound with a novel and promising mechanism of action, in a Phase IIa cancer trial, after receipt of an Investigational New Drug (IND) approval from AFSSAPS, Agence Francaise de Securite Sanitaire des Produits de Sante.

  • Cephalon, Inc (Cephalon), ImmuPharma's partner for Rigerimod (LupuzorTM),  commenced the recruitment of lupus patients for a Phase IIb trial being conducted largely in the US.  This study has been designed to provide US-based investigators and the US FDA with clinical data obtained mainly in the USA.  The data generated from this trial will be part of the package to be submitted to the FDA and other regulatory authorities for approval.  Positive Phase IIb data from outside the USA has previously been announced.

  • Cephalon has also initiated development of LupuzorTM in Japan through its partner Symbio Pharmaceuticals.

  • ImmuPharma remains committed to its other compounds in R&D.

  • Strong cash position of £20m (as at 30 June 2010).

  • Received Best Drug Development Company in Europe 2010 Award from the New Economy.

  • Basic and diluted loss per share were 0.10p and 0.10p respectively (31 December 2009:  basic and diluted earnings per share 10.46p and 9.99p respectively).

 

Click here for more details


London, 28 September 2010

 

Notification of Interim Results

ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, is scheduled to announce its Interim Results for the six months ended 30 June 2010 on Thursday 30th September 2010.

 

Click here for more details


London, 23 June 2010

 

Cephalon, ImmuPharma license partner for Rigerimod (Lupuzor) initiates critical steps in its development program
US Recruitment commences

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce today that Cephalon Inc., its license partner for IPP-201101 (Rigerimod; Lupuzor) has started the recruitment of lupus patients for a Phase IIb trial in the US. This study was designed to allow US based investigators and the FDA to evaluate Rigerimod (Lupuzor) as a treatment for lupus before commencing a Phase III clinical trial. A large number of centres are involved and the study is expected to be extended to EU sites within a few months. The data generated from this trial will be part of the package to be submitted to the FDA and other regulatory authorities for approval.

 

Click here for more details


London, 17 June 2010

 

Result of Annual General Meeting

ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.

 

Click here for more details


London, 10 June 2010

 

Annual Report and Accounts
Notice of Annual General Meeting : 17 June 2010

In accordance with Rule 20 of the AIM Rules, ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2009, has been posted to shareholders.

 

Click here for more details


London, 19 May 2010

ImmuPharma receives approval for
Initiation of PhaseI/IIA Studies in Cancer

ImmuPharma plc (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that it received an Investigational New Drug (IND) approval from AFSSAPS, Agence Francaise de Securite Sanitaire des Produits de Sante, for a Phase I/IIa study in patients of  IPP-204106, its anti-cancer compound with a novel and promising mechanism of action.  The first patients are expected to be dosed within the next few weeks.

 

Click here for more details


London, 19 May 2010

PRELIMINARY RESULTS ANNOUNCEMENT
for the year ended 31 December 2009

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2009.

Key Highlights:

Revenue reported of £22 million for the period following the receipt of $30 million from Cephalon, Inc. as a license payment for LupuzorTM in February, 2009

Basic and diluted earnings per share were 10.46p and 9.99p respectively (31 December 2008:  6.23p and 6.07p respectively)

Strong cash position of £22.5 million.  Cash balance resulting from LupuzorTM agreement to be used to develop the other promising compounds in the pipeline

Lead candidate for the treatment of Lupus, LupuzorTM, licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties.  $45m in cash received to date - $15m in Q4 2008 and $30m in Q1 2009

Final results of the Phase IIb study of LupuzorTM showed a clinically significant improvement in patient response rate versus placebo

Received IND approval from AFSSAPS, Agence Francaise de Securite Sanitaire des Produits de Sante, for a Phase I/IIa study in patients, IPP-204106, our anti-cancer compound with a novel and promising mechanism of action.  First patients expected to be dosed within the next few weeks

Received numerous awards during the year, including:  'Breakthrough of the Year 2009' European Mediscience Award, 'Best Technology 2009' AIM Award and 'Best Drug Development Company Europe 2010' New Economy Award.

 

Click here for more details


London, 8 April 2010

Best Drug Development Company in Europe Award

ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company, has been voted "Best Drug Development Company, Europe" at The New Economy Pharmaceutical & Healthcare Awards 2010.

This award follows on from two notable wins in 2009 namely; "Best Technology Award" at the AIM Awards, organized by the London Stock Exchange and "Breakthrough of the year 2009" at the European Mediscience Awards.

 

Click here for more details


London,  5 January 2010

Additional Listing and Total Voting Rights

Following the receipt of a notice of exercise of options, application has been made to the London Stock Exchange for the admission of 365,000 new ordinary shares to trading on AIM.   The admission of the new ordinary shares will become effective today. The new ordinary shares rank pari passu with the existing ordinary shares of the Company.

 

Click here for more details


London, 5 January 2010

ING take 4% stake in ImmuPharma plc 

ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company is pleased to announce that ING, Belgium (ING) has taken a 4% stake in the company with the exercise of warrants issued in December 2006.  These warrants were exercised on 24 December 2009.

 

Click here for more details


2010 | 2009 | 2008 | 2007 | 2006